How Our Algorithm Models the Drug Discovery Process

Jul 14, 2020 | Blog | 0 comments

Daniel Gigante

As I mentioned in my previous post, our CEO, Andrew Satz, recently spoke at “Alumni in Conversation,” hosted by Columbia University School of General Studies. During the discussion, Andrew explained how EVQLV’s algorithm models the drug discovery process. See below.

As Andrew explains, the traditional way of discovering antibodies involves injecting an animal with a disease or a virus. The animal is then going to have an immune response, producing antibodies to fight the disease. You then have an animal antibody that you now need to convert into a human antibody. This process takes roughly 4-5 years and cost over half a billion dollars.

At EVQLV, we model that entire process in the computer. In the above example, the process by which the animal is forming its immune response is evolutionary. Our algorithm models this evolutionary process in the computer, allowing us to generate millions of antibodies at a fraction of the cost and time it takes to do so in the lab. After we’ve generated our algorithms, we screen them so they’re less likely to have failure in animals or in humans. In short, we’re moving from drug discovery to computational drug design.

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *

NY Bio-Computation Startup EVQLV Closes Financing Round

NEW YORK, February 8, 2021 -- EVQLV, an innovator in developing artificial intelligence to accelerate how biologic therapies reach patients, today announced the closing of a funding round that will be used to advance the company’s R&D efforts, boost development...

EVQLV Welcomes Operations & Finance Lead Alexander Sonneborn

NEW YORK, February 1, 2021 -- EVQLV is pleased to announce that Alexander Sonneborn has joined EVQLV to oversee company operations and finances. After an early career in the life sciences, Alexander transitioned to entrepreneurial activities in technology-based...

EVQLV Submits 1 Million Ab Initio Derived Sequences for Validation

NEW YORK, January 12, 2021 - EVQLV has submitted one million AI-generated sequences for independent laboratory validation in fulfillment of the second phase of a project with its collaborator. The first phase of the project consisted of 100 antibody sequences based...

Fully Automated Rabbit Humanization Project Initiated w/ U Buffalo

NEW YORK, December 16, 2020 -- EVQLV is eagerly anticipating the results from the second phase of their University at Buffalo rabbit-humanization collaboration. Starting with rabbit monoclonal antibodies, EVQLV is attempting to validate its fully-automated...

EVQLV Accepted to Prestigious Techstars Boston Accelerator

NEW YORK, November 18, 2020 -- EVQLV, a New York company that uses AI to accelerate the development of antibodies, will be one of 10 startups in the new class of the Techstars Boston program. This year’s program will be 100% virtual and, for the first time, will...

Pin It on Pinterest